anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a piece of functional bread for treating the cardiovascular disease, and a making method of the functional bread. The bread comprises 70 parts to 100 parts of coarse grain powder, 30 parts to 50 parts of composite functional powder, 6 parts to 8 parts of vegetable oil, 10 parts to 15 parts of egg white, 1.5 parts to 2.5 parts of nutrition additives, 0.002 part to 0.003 part of bread improver, 0.01 part to 0.02 part of corrigent, 0.3 part to 0.5 part of active dry yeast, 0.6 part to 1.0 part of edible salt and 5 parts to 10 parts of acacia honey. The coarse grain powder is the mixture of corn flour, green bean powder, rice bran, wheat bran, adlay powder, whole wheat flour and strong flour. The composite functional powder is the mixture of inonotus obliquus powder, celery seed powder, locust flower powder, kelp powder, hawthorn powder, wild salviae miltiorrhizae powder, yam flour and onion powder. The vegetable oil is the mixture of olive oil, perilla oil and garlic oil. The bread is good in taste, abundant in nutrient and low in fatty acid content, contains a certain number of Chinese medicine components and has a good dietary therapy effect on patients with the cardiovascular disease.
A computer-implemented method and system for screening for and monitoring a condition are provided. In a method conducted at a communication device a virtual environment is provided which is output to a user via one or more output components of the communication device. The user is required to interact with the environment by way of a series of instructions input into the communication device. The virtual environment includes a number of environment-based discriminators which, based on a user's interaction relative thereto, facilitate discrimination between a user with and without a condition. Data points relating to the user's interaction in relation to each of the number of environment-based discriminators are recorded and compiled into a payload including a user identifier. The payload is output for input into a machine learning component configured to discriminate between users with and without the condition by identifying patterns in the data points.
Patients scheduled for elective abdominal surgery by laparotomy (general surgery or gynaecological surgery) will receive a thoracic epidural (around T9-T10/T10-T11) and general anesthesia. Apart from standard monitoring, the ANI (derived from the EKG) and the NoL index (obtained via a finger probe) will be recorded. The epidural catheter will be injected with 6-10 ml of lidocaine 2% with epinephrine 5 mcg/ml to produce anesthetic level of neuraxial blocade and then be perfused with the same solution at 4-8 ml/hour. After incision and confirmation of adequate blocade with the epidural local anesthetic, the patient will receive a series of painful electric stimulation with a standard nerve stimulator applied over the ulnar nerve in tetanic mode for 30 seconds at 100 Hz and 70mA. Each stimulation will occur at a different rate of infusion of IV remifentanil at steady state (0,005 mcg/kg/min; 0,05 mcg/kg/min; 0,1 mcg/kg/min; 0,15 mcg/kg/min). A stimulation at 0,005 mcg/kg/min will be done before and after epidural loading with local anesthetics to look for altered variations in analysed parameters. The variation and the kinetic of the variations after stimulations will be observed for heart rate, mean blood pressure, BIS, ANI and NoL index.
PURPOSE:To obtain a composition for cleansing, good in extensibility in application to the skin, having good permeability to fine parts and excellent in feeling of use by using a hydrophilic nonionic surfactant, a cationic surfactant, a water- soluble compound having hydroxyl group, a liquid oil and water together. CONSTITUTION:The composition for cleansing is obtained by using a hydrophilic nonionic surfactant (e.g. a surfactant such as a polyoxyethylene alkyl ether having >9 HLB), a cationic surfactant (e.g. dodecyltrimethylammonium chloride), a water-soluble compound having hydroxyl group (e.g. propylene glycol), a liquid oil (e.g. liquid paraffin) and water together. This composition for cleansing is a transparent or translucent gelatinous or liquid composition. This composition is a readily handleable gelatinous or liquid form, excellent in feeling of use such as extensibility, slipperiness, etc., and good in permeability to fine parts. The composition is capable of performing the massaging while maintaining smooth touch during application without easily thickening even by mixing of water from the outside and can be used in bathrooms, etc.
Patients will receive the best medical treatment according to local guidelines, including antiplatelet agents, anticoagulants, thrombolysis, etc., but not any EVT. In the control arm, rescue EVT is allowed in patients with disease progression leading to an increase in NIHSS≥4 and excluding the impact of non-stroke factors, and the onset-to-treatment time is within 24 hours.This may include, but not limited to, stent-retriever thrombectomy, aspiration thrombectomy, intra-arterial thrombolysis, balloon angioplasty, stent implantation and so on.
Drug: zanubrutinib,160 mg oral capsules twice daily for 12 months Drug: Bendamustine,70-90 mg/m2 on days 1 and 2 of each cycle for 6 cycles. Drug: Rituximab,375 mg/m2 intravenously on day 0 of each cycle for 6 cycles.
Activation of the maternal immune system leads to a downstream cascade of proinflammatory events that culminate in the activation of spontaneous uterine contractions, which is associated with preterm birth. Ras-related C3 botulinum toxin substrate 1 (Rac1) is a crucial protein related to cell contraction and inflammation. The main purpose of this study was to explore the role and function of Rac1's regulation of inflammation through in- vivo and in-vitro experiments. Rac1 inhibitor was used in animal model of preterm birth and cells isolated from the uterine tissues of pregnant mice on gestational day 16 were transfected with adenovirus to knockdown or overexpress Rac1 and treated with the Calcium-calmodulin-dependent protein kinase II (CaMKII) inhibitor KN93. The expression of Rac1, uterine contraction-associated proteins (CAPs) (COX-2 and Connexin43), and inflammatory cytokines, were assessed by Western blotting and RTPCR. LPS upregulated Rac1, COX-2 and Connexin43 expression in uterine smooth muscle cells (USMCs). The expression of inflammatory cytokines, COX-2, and Connexin43 was significantly decreased in shRac1-transfected cells compared with cells stimulated with LPS only. Rac1 overexpression led to an increase in the expression of inflammatory cytokines, COX-2, and Connexin43. Furthermore, after Rac1 overexpression, KN93 reduced the expression of uterine contraction-associated proteins and inflammatory cytokines. It is thought that the effect of Rac1 on inflammatory cytokine and contraction-associated protein expression in USMCs is mediated by CaMKII. Rac1 can modulate the expression of contraction-associated proteins and inflammatory cytokines through the CaMKII pathway. Rac1 could be an effective therapeutic target for improving the outcome of preterm birth.
Amyotrophic lateral sclerosis (ALS) is an adult-onset progressive neurodegenerative disorder characterized by the loss of upper and lower motor neurons in the brain and spinal cord. Accumulating evidence suggests that ALS is not solely a neuronal cell- or brain tissue-autonomous disease and that neuroinflammation plays a key role in disease progression. Furthermore, whereas both CD4 and CD8 T cells were observed in spinal cords of ALS patients and in mouse models of the disease, their role in the neuroinflammatory process, especially considering their functional changes with age, is not fully explored. In this study, we revealed the structure of the CD4 T-cell compartment during disease progression of early-onset SOD1G93A and late-onset SOD1G37R mouse models of ALS. We show age-related changes in the CD4 T-cell subset organization between these mutant SOD1 mouse models towards increased frequency of effector T cells in spleens of SOD1G37R mice and robust infiltration of CD4 T cells expressing activation markers and the checkpoint molecule PD1 into the spinal cord. The frequency of infiltrating CD4 T cells correlated with the frequency of infiltrating CD8 T cells which displayed a more exhausted phenotype. Moreover, RNA-Seq and immunohistochemistry analyses of spinal cords from SOD1G37R mice with early clinical symptoms demonstrated immunological trajectories reminiscent of a neurotoxic inflammatory response which involved proinflammatory T cells and antigen presentation related pathways. Overall, our findings suggest that age-related changes of the CD4 T cell landscape is indicative of a chronic inflammatory response, which aggravates the disease process and can be therapeutically targeted.
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to a novel derivative of benzimidazole of the formula (I)   where A means a single bond or C 1-2 - alkylene group; R 6  means hydrogen atom or C 1-4 - alkyl group; B means C 2-3 - alkylene group; X means oxygen atom; each of R 1  and R 2  means hydrogen atom; E means C 1-2  alkylene group; R 3  means phenyl group (this phenyl group can be optionally substituted with halogen atom); each of R 4  and R 5  that do not dependent each of other means hydrogen atom or C 1-4 - alkyl group; D means C 1-4 - alkylene group and Ar means phenyl group (this phenyl group can be optionally substituted with halogen atom, C 1-4 - alkyl group, C 1-4 - alkoxy-group or trifluoromethyl group). Invention describes also an agent showing an antagonistic activity against substance P and an antihistaminic activity. Invention can be used in the field of chemistry and medicine. EFFECT: new compound indicated above, valuable medicinal properties. 6 cl, 4 tbl, 28 ex
The invention relates to a wet tissue. A wet tissue is made of a non-woven fabric. Sunscreen is evenly coated onto the non-woven fabric. The sunscreen contains a skin moisturizing component and a sterilizing component. The wet tissue is suitable for outdoor use in summer. By using the wet tissue, not only can the skin be cleaned, but also the skin can be moisturized, the sun is screened, the trouble that users carry with skin moisturizer and sunscreen is avoided and the outgoing is facilitated.
Background Black individuals with chronic musculoskeletal (MSK) pain tend to experience worse pain and opioid use-related outcomes, including other substance co-use, compared with non-Hispanic White individuals. Co-using cannabis with opioids could instigate a cascade of pain-related vulnerabilities and poor outcomes. Here, we test associations between cannabis/opioid co-use and pain-related outcomes among Black individuals with chronic MSK pain. Methods Black adults with chronic MSK pain who use opioids (N=401; 51.62% female, Mage=35.90, SD=11.03) completed online measures of pain intensity/interference, emotional distress, opioid dependence, and risky use of other substances. Results Compared with opioid use alone, opioid and cannabis co-use was associated with elevated anxiety and depression symptoms, opioid dependence, and risky substance use, but not pain. Conclusions Black individuals with chronic MSK pain who co-use opioids and cannabis warrant targeted interventions that address their needs. Tailored interventions could help address disparities in pain-related outcomes and opioid morbidity and mortality rates.
This is a multicentre, randomized, double-blind, placebo-controlled trial that aims to investigate the efficacy and safety of (early and late) initiation treatment of Edaravone Dexborneol versus placebo in patients with acute ischemic stroke, and to explore the optimal time window for "brain cell protective therapy" of Edaravone Dexborneol. Patients who were eligible to the inclusion criteria and ineligible to the exclusion criteria will be stratified by time to trial drug: early (\<3 hours) and late (3-6 hours). Then each layer will be randomly assigned into two groups by a 1:1 ratio after the ICF was received. Patients in one arm will be given 15ml edaravone and dexborneol concentrated solution for injection (37.5mg, containing edaravone 30mg and dexborneol 7.5mg) twice a day for 10-14 days, and those in the other arm will be given an equivalent placebo drug. All patients will be followed up for 90 days. The primary outcome is the proportion of modified Rankin Scale 0-2 and the safety outcome is the proportion of severe adverse events.
A medical history-taking device 20 for use by a patient is about the size of a book and has a screen 22 for displaying questions to a patient, a limited number of keys 26 by which the patient can enter answers, and a memory for storing the patient's answers. The device is battery-powered for portability and uses a low-power liquid crystal display or the like to display instructions and medical questions to the patient. Only four keys are seen or used by the patient for answering the questions: YES, NO, NOT SURE, and NEXT QUESTION. Additional control keys 36 used by the medical staff are hidden from the patient. The device is controlled by a pre-programmed microcomputer on a chip, and contains a ROM-based, removable and replaceable program cartridge 38b which contains the questions. The device collects the patient's answers, and drives a remote printer or computer terminal which provides an output of the medical history. <IMAGE>
In this health promotion program, a pilot intervention study will be implemented to assess the effects of three different health promoting / suicide prevention programs in 11,000 students across 11 European countries (Sweden, Austria, Estonia, France, Germany, Hungary, Ireland, Israel, Italy, Romania, Slovenia and Spain): 1. A general health promotion program targeting students' awareness on healthy/unhealthy behaviours and students' self-efficacy in diminishing unhealthy behaviours; 2. ProfScreen - screening by professionals of at-risk students through a questionnaire. For adolescents identified as high risk (screen positives) the program includes referral to mental health treatment and ensuring compliance. 3. QPR (Question, Persuade \& Refer) - a gatekeepers' program, training all adult staff at schools (teachers, counselors, nurses etc.) and parents on how to recognize \& refer a student with risk-taking behaviours or suffering from mental illness to mental-health help resources.

Each of these prevention programs uses a different active component in order to be successful. The first prevention program empowers the students by increasing their self-efficacy. The second prevention program (ProfScreen) empowers mental health professional in identifying subjects at risk. The third program (QPR) empowers teachers and parents in at-risk case finding and referring to mental health facilities. The registration of the complete RCT is available on the German Clinical Trials Registry (DRKS00000214).
The coronavirus disease 2019 (COVID-19) pandemic has caused significant medical, social, and economic impacts globally, both in the short and long term. Although most individuals recover within a few days or weeks from an acute infection, some experience longer lasting effects. Data regarding the postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection (PASC) in children, or long COVID, are only just emerging in the literature. These symptoms and conditions may reflect persistent symptoms from acute infection (eg, cough, headaches, fatigue, and loss of taste and smell), new symptoms like dizziness, or exacerbation of underlying conditions. Children may develop conditions de novo, including postural orthostatic tachycardia syndrome, myalgic encephalomyelitis/chronic fatigue syndrome, autoimmune conditions and multisystem inflammatory syndrome in children. This state-of-the-art narrative review provides a summary of our current knowledge about PASC in children, including prevalence, epidemiology, risk factors, clinical characteristics, underlying mechanisms, and functional outcomes, as well as a conceptual framework for PASC based on the current National Institutes of Health definition. We highlight the pediatric components of the National Institutes of Health-funded Researching COVID to Enhance Recovery Initiative, which seeks to characterize the natural history, mechanisms, and long-term health effects of PASC in children and young adults to inform future treatment and prevention efforts. These initiatives include electronic health record cohorts, which offer rapid assessments at scale with geographical and demographic diversity, as well as longitudinal prospective observational cohorts, to estimate disease burden, illness trajectory, pathobiology, and clinical manifestations and outcomes.
This invention is a medicine combination for curing peptic ulcer. Its feature is that it contains fade melanin or L-tryptophan, and at least one kind of pylorus spirabacteria inhibitor or gastric acid secretion inhibitor. Pylorus spirabacteria inhibitor is selected from penicillin, ampicillin, metronidazole furazolidone etc. And gastric acid secretion inhibitor is lafutidine, famotidine, roxatidine, tenatoprazole, latamoxef sodium, rabeprazole, pantoloc, aluminum hydroxide, magnesium hydroxide, baking soda and calcium carbonate. The compound can be make into granule, effervesce agent, tablet, capsule, molasses, injection, suspensoid injection, suppository or sustained-release preparations. It is taken by oral administration or non-oral administration path. It achieves the goal of preventing and curing gastric ulcer and duodenal ulcer by effectively clear oxygen-derived free radicals, inhibiting grown of pylorus spirabacteria and gastric acid secretion.
A gold nano vesicle modified by poly-sarcosine, its preparation method and application, its surface is hydrophilic poly-sarcosine, hydrophobic shell is formed by orderly stacking biodegradable polycaprolactone and gold nano particles. Through ligand exchange method, polymer can be modified on surface of gold nano particles effectively, and then through self-assembly method, gold nano vesicles modified by poly sarcosine are prepared. The size of the gold nano vesicle can be controlled to be 50-250nm by regulating and controlling the structure of the polymer, the size of the gold nano particles and a self-assembly method. The hydrophilic cavity of the gold nanovesicle can be used for loading water-soluble drugs, and the hydrophobic shell can be used for loading oil-soluble drugs. The gold nano vesicle has good biocompatibility, can effectively load the medicine, avoids the leakage of the medicine, realizes the accurate and rapid release of the medicine under the illumination condition, improves the curative effect of the medicine, and reduces the toxic and side effects of the medicine. The invention discloses a preparation method thereof.
PURPOSE: To provide an acetoaminophene tablet having characteristic including particularly high hardness and short elution time. CONSTITUTION: This table is produced from (a) acetoaminophene of 85 to 95% w/w of the dry weight of the entire compsn., (b) polyvinyl pyrrolidone(PVD) of 4 to 5% w/w of the dry weight of the entire compsn., (c) a disintegrator of 1 to 10% w/w of the dry weight of the entire compsn. and (d) a suitable amt. of a preferable lubricant. The acetoaminophene is put into a fluidized bend granule producing device and a soln. of 5 to 10% polyvinyl pyrrolidone(PVD) is sprayed to the fluidized bed. The fluidized bed is dried to its humidity of 0.5 to 2% w/w and finally, the disintegrator is added and the mixture is directly tableted.
Pruritus (synonymous "itch") is the commonest skin-related symptom caused by numerous dermatological and non-dermatological conditions. Chronic pruritus (CP) defined by a duration of \> 6 weeks is associated with significantly impaired quality of life and high socio-economic burden. At present, a data registry to monitor and compare clinical presentation, treatment outcomes and safety issues of these patients is lacking in Switzerland. The implementation of the SWITCHR could help to i.) improve medical care of CP patients, ii.) allow standardised comparison of different pruritic conditions as well as national data with international CP populations and iii.) raise the awareness for CP in general practitioners, health care institutions, national public health authorities and pharmaceutical companies within Switzerland.
Tamsulosin 0.4 mg is a drug belonging to the category of alpha-blocker drugs used as first choice drugs (according to European Urology association guidelines) for the treatment of benign prostatic hyperplasia. The recommended dose is 0.4 mg per day (1 administration), to be taken preferably at the same time during the day, indifferently with or without meals.
A pharmaceutical two-phase admixture for topical application, transdermal or transmucosal, characterized by components in two phases, a liquid and a solid, adapted for topical application, transdermal or transmucosal, to various skin and/or mucosal surface areas of the body is disclosed. The solid phase is comprised of one or more bio-identical hormones and the liquid phase is comprised of one or more excipient carrier oils. The bio-identical hormone component is comprised of one or more of Bi-Est, testosterone, progesterone, and dehydroepiandrosterone. The excipient carrier oil component is comprised of one or more of a wide range of common and rare pharmacological oils including specific formulations of jojoba oil, evening primrose oil, and borage seed oil. The solid phase bio-identical hormone component is comprised of either a standard coarse formulation or a formulation comprised of nanoparticles. The pharmaceutical admixture is especially useful in a regime of hormone replacement therapy.
Two capsules of cinnamon 500mg twice per day after meals (2g/day). All capsules will be given simultaneously with the clomiphene citrate medication (standard treatment for infertility in women with PCOS). Participants will be asked to keep their normal lifestyle including daily food and physical activity level.
There are no known absolute contraindications to diagnostic testing or hyposensitization with allergen immunotherapy. 

Patients with cardiovascular disease or pulmonary disease such as symptomatic asthma, and/or who are receiving cardiovascular drugs such as beta blockers, may be at higher risk for severe adverse reactions. These patients may also be more refractory to the normal anaphylaxis treatment regimen. 

Immunotherapy is not generally indicated when the offending allergen(s) can be effectively eliminated or minimized by environmental control. There are differences of opinion on the possibility of routine immunizations exacerbating autoimmune diseases. The evidence has been inconclusive. Therefore, caution should be exercised in administering immunotherapy to patients with other immunologic diseases and only administered if the risk from exposure to the allergen is greater than the risk of exacerbating the underlying disorder. Injections should be avoided in patients with a bleeding tendency.